PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 229
- Registration Number
- NCT00502242
- Locations
- ๐ฟ๐ฆ
Pfizer Investigational Site, Cape Town, Western Cape, South Africa
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
Phase 3
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1053
- Registration Number
- NCT00500266
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- Biological: ACC-001 + QS-21Biological: QS-21Biological: ACC-001
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00498602
- Locations
- ๐บ๐ธ
Barnes-Jewish Hospital, St. Louis, Missouri, United States
๐บ๐ธBarrnes-Jewish Hospital at Washington University, St. Louis, Missouri, United States
๐บ๐ธCUMC Research Pharmacy, New York, New York, United States
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis
Phase 4
Completed
- Conditions
- Candidiasis
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2011-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 282
- Registration Number
- NCT00496197
- Locations
- ๐ฐ๐ท
Pfizer Investigational Site, Seoul, Korea, Republic of
A Phase 2 Study Of PF-00232798 In HIV Positive Patients
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 43
- Registration Number
- NCT00495677
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Koeln, Germany
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 82
- Registration Number
- NCT00494091
- Locations
- ๐ฐ๐ท
Pfizer Investigational Site, Seoul, Korea, Republic of
Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
Phase 3
Completed
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccineBiological: 13vPnC + TIV
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1185
- Registration Number
- NCT00492557
A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1028
- Registration Number
- NCT00488488
Observational Trial With Enbrel
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4945
- Registration Number
- NCT00488475
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Muenster, NRW, Germany
Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients
Phase 2
Withdrawn
- Conditions
- Human Immunodeficiency Virus
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00488995
ยฉ Copyright 2025. All Rights Reserved by MedPath